Assessment of the Accuracy of PET/MR in Detection and Monitoring Response of Bone Metastases

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04159376

Enrollment

150

Registered

2019-11-12

Start date

2019-12-25

Completion date

2021-12-25

Last updated

2019-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Metastases

Brief summary

The great promise of PET/MR for assessment of skeletal metastatic involvement is derived from the extensive experience with stand- alone MR, but initial data on the use of PET/MR for assessment of bone pathology indicate that PET/MR introduces unique issues that should be addressed when determining its role in this clinical scenario. In this study cohort includes 150 patients 18 years or older, having metastatic skeletal involvement on baseline PET/CT prior to treatment. Baseline studies and follow up studies of the patients referred post treatment, will be reviewed. The main goal of the study is to asses the accuracy of PET/MR in detection and monitoring response of bone metastases.

Interventions

DIAGNOSTIC_TESTPET/MR

All patients will have a PET/CT and PET/MR study performed at the same clinical setting using a single dose of tracer administration. The study cohort includes 150 patients 18 years or older, having metastatic skeletal involvement on baseline PET/CT prior to treatment. Baseline studies and follow up studies of the patients referred post treatment, will be reviewed. The tracers will be FDG, labelled PSMA labelled Somatostatin and F-DOPA in order to assess skeletal lesions detection of all tumor types. Skeletal lesions will be divided into marrow-based lesions, lytic, blastic and scleroric lesions. Tracer uptake will be measured at baseline and after treatment. Metabolic PET parameters, CT appearance and MR parameters will be assessed. The best MR-based attenuation algorithm for detection of lesions and monitoring response will be derived.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

150 patients having metastatic skeletal involvement on baseline PET/CT prior to treatment

Exclusion criteria

1. Age \<18. 2. Pregnant or breast feeding patients.

Design outcomes

Primary

Measure	Time frame	Description
The investigators will report about the number of patients who preformed PET/MR for assessment of skeletal involvement as well as activity after treatment,	1 year	and also preformed in routine PET/CT and to optimize the algorithm of MR-based attenuated PET images.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026